Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis

References

• BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• SparanoJA, GrayRJ, RavdinPM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380(25):2395–2405. doi:10.1056/NEJMoa190481931157962
   PubMed Web of Science ®Google Scholar
• SiegelRL, MillerKD, JemalA. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-015894097
   PubMed Web of Science ®Google Scholar
• TevaarwerkAJ, GrayRJ, SchneiderBP, et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 2013;119(6):1140–1148. doi:10.1002/cncr.2781923065954
   PubMed Web of Science ®Google Scholar
• VoogdA, NielsenM, PeterseJ, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19(6):1688–1697. doi:10.1200/JCO.2001.19.6.168811250998
   PubMed Web of Science ®Google Scholar
• VilaJ, TeshomeM, TuckerSL, et al. Combining clinical and pathologic staging variables has prognostic value in predicting local-regional recurrence following neoadjuvant chemotherapy for breast cancer. Ann Surg. 2017;265(3):574–580. doi:10.1097/SLA.000000000000149227735826
   PubMed Web of Science ®Google Scholar
• van MaarenMC, de MunckL, StrobbeLJA, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study. Int J Cancer. 2019;144(2):263–272. doi:10.1002/ijc.3191430368776
   PubMed Web of Science ®Google Scholar
• PoorvuP, GelberS, RosenbergS, et al. Prognostic Impact of the 21-gene recurrence score assay among young women with node-negative and node-positive ER-positive/HER2-negative breast cancer. J Clin Oncol. 2020;38(7):725–733. doi:10.1200/JCO.19.0195931809240
   PubMed Web of Science ®Google Scholar
• SestakI, BuusR, CuzickJ, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):545–553. doi:10.1001/jamaoncol.2017.552429450494
   PubMed Web of Science ®Google Scholar
• VoducKD, CheangMC, TyldesleyS, GelmonK, NielsenTO, KenneckeH. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684–1691. doi:10.1200/JCO.2009.24.928420194857
   PubMed Web of Science ®Google Scholar
• WarrenLE, LigibelJA, ChenYH, TruongL, CatalanoPJ, BellonJR. Body Mass index and locoregional recurrence in women with early-stage breast cancer. Ann Surg Oncol. 2016;23(12):3870–3879. doi:10.1245/s10434-016-5437-327448118
   PubMed Web of Science ®Google Scholar
• NguyenP, TaghianA, KatzM, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26(14):2373–2378. doi:10.1200/JCO.2007.14.428718413639
   PubMed Web of Science ®Google Scholar
• CorsoG, MaisonneuveP, MassariG, et al. Validation of a novel nomogram for prediction of local relapse after surgery for invasive breast carcinoma. Ann Surg Oncol. 2020;27(6):1864–1874. doi:10.1245/s10434-019-08160-731965372
   PubMed Web of Science ®Google Scholar
• Stuart-HarrisR, DahlstromJE, GuptaR, ZhangY, CraftP, ShadboltB. Recurrence in early breast cancer: analysis of data from 3765 Australian women treated between 1997 and 2015. Breast. 2019;44:153–159. doi:10.1016/j.breast.2019.02.00430785024
   PubMed Web of Science ®Google Scholar
• TaghianA, JeongJH, MamounasE, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2004;22(21):4247–4254.15452182
   PubMed Web of Science ®Google Scholar
• WapnirI, AndersonS, MamounasE, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24(13):2028–2037. doi:10.1200/JCO.2005.04.327316648502
   PubMed Web of Science ®Google Scholar
• TanisE, van de VeldeC, BartelinkH, van de VijverM, PutterH, van der HageJ. Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer. Eur J Cancer. 2012;48(12):1751–1756. doi:10.1016/j.ejca.2012.02.05122446021
   PubMed Web of Science ®Google Scholar
• BelkacemiY, HannaNE, BesnardC, MajdoulS, GligorovJ. Local and regional breast cancer recurrences: salvage therapy options in the new era of molecular subtypes. Front Oncol. 2018;8:112. doi:10.3389/fonc.2018.0011229719816
   PubMed Web of Science ®Google Scholar
• HolleczekB, StegmaierC, RadosaJC, SolomayerEF, BrennerH. Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis - results from a registry-based study from Germany. BMC Cancer. 2019;19(1):520. doi:10.1186/s12885-019-5710-531146706
   PubMed Web of Science ®Google Scholar
• HuntKK, BallmanKV, McCallLM, et al. Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg. 2012;256(3):428–436. doi:10.1097/SLA.0b013e318265449422868365
   PubMed Web of Science ®Google Scholar
• MillarEK, GrahamPH, O’TooleSA, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 2009;27(28):4701–4708. doi:10.1200/JCO.2008.21.707519720911
   PubMed Web of Science ®Google Scholar
• JwaE, ShinKH, KimJY, et al. Locoregional recurrence by tumor biology in breast cancer patients after preoperative chemotherapy and breast conservation treatment. Cancer Res Treat. 2016;48(4):1363–1372. doi:10.4143/crt.2015.45626910473
   PubMed Web of Science ®Google Scholar
• FitzalF, FilipitsM, RudasM, et al. The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. Br J Cancer. 2015;112(8):1405–1410. doi:10.1038/bjc.2015.9825867274
   PubMed Web of Science ®Google Scholar
• GeffenD. Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both?Ann Oncol. 2018;29(5):1096–1098. doi:10.1093/annonc/mdy11529635411
   PubMed Web of Science ®Google Scholar
• Bustamante EduardoM, PopoviciV, ImbodenS, et al. Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases. BMC Cancer. 2019;19(1):549. doi:10.1186/s12885-019-5752-831174485
   PubMed Web of Science ®Google Scholar
• SparanoJA, GrayRJ, MakowerDF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–121. doi:10.1056/NEJMoa180471029860917
   PubMed Web of Science ®Google Scholar
• TongY, WuJ, HuangO, et al. 21-gene recurrence score and adjuvant chemotherapy decision for breast cancer patients with positive lymph nodes. Sci Rep. 2019;9(1):13123. doi:10.1038/s41598-019-49644-631511599
   PubMed Web of Science ®Google Scholar
• LuY, TongY, HuangJ, et al. Primary 21-gene recurrence score and disease outcome in loco-regional and distant recurrent breast cancer patients. Front Oncol. 2020;10:1315. doi:10.3389/fonc.2020.0131532850415
   PubMed Web of Science ®Google Scholar
• MamounasEP, TangG, FisherB, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28(10):1677–1683. doi:10.1200/JCO.2009.23.761020065188
   PubMed Web of Science ®Google Scholar
• MamounasEP, LiuQ, PaikS, et al. 21-gene recurrence score and locoregional recurrence in node-positive/ER-positive breast cancer treated with chemo-endocrine therapy. J Natl Cancer Inst. 2017;109(4):djw259. doi:10.1093/jnci/djw259
   PubMedGoogle Scholar
• JegadeeshNK, KimS, PrabhuRS, et al. The 21-gene recurrence score and locoregional recurrence in breast cancer patients. Ann Surg Oncol. 2015;22(4):1088–1094. doi:10.1245/s10434-014-4252-y25472643
   PubMed Web of Science ®Google Scholar
• ThakerNG, HoffmanKE, StauderMC, et al. The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. Springerplus. 2015;4(1):36. doi:10.1186/s40064-015-0840-y25674496
   PubMedGoogle Scholar
• SolinLJ, GrayR, GoldsteinLJ, et al. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat. 2012;134(2):683–692. doi:10.1007/s10549-012-2072-y22547108
   PubMed Web of Science ®Google Scholar
• ZhuS, WuJ, HuangO, et al. Clinicopathological features and disease outcome in breast cancer patients with hormonal receptor discordance between core needle biopsy and following surgical sample. Ann Surg Oncol. 2019;26(9):2779–2786. doi:10.1245/s10434-019-07480-y31144143
   PubMed Web of Science ®Google Scholar
• WuJ, FangY, LinL, et al. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. Oncotarget. 2017;8(24):38706–38716. doi:10.18632/oncotarget.1631328404972
   PubMedGoogle Scholar
• PaikS, TangG, ShakS, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–3734. doi:10.1200/JCO.2005.04.798516720680
   PubMed Web of Science ®Google Scholar
• GeyerCEJr., TangG, MamounasEP, et al. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer. 2018;4(1):37. doi:10.1038/s41523-018-0090-630456299
   PubMed Web of Science ®Google Scholar
• HudisCA, BarlowWE, CostantinoJP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25(15):2127–2132. doi:10.1200/JCO.2006.10.352317513820
   PubMed Web of Science ®Google Scholar
• McGuireA, LoweryAJ, KellMR, KerinMJ, SweeneyKJ. Locoregional recurrence following breast cancer surgery in the trastuzumab era: a systematic review by subtype. Ann Surg Oncol. 2017;24(11):3124–3132. doi:10.1245/s10434-017-6021-128755141
   PubMed Web of Science ®Google Scholar
• ElsayedM, AlhussiniM, BashaA, AwadAT. Analysis of loco-regional and distant recurrences in breast cancer after conservative surgery. World J Surg Oncol. 2016;14(1):144. doi:10.1186/s12957-016-0881-x27180041
   PubMed Web of Science ®Google Scholar
• CorsoG, MaisonneuveP, SantomauroG, et al. Ipsilateral breast tumor reappearance and contralateral breast cancer after primary breast cancer treatment: a comprehensive retrospective study of 15,168 patients. Oncology. 2018;95(3):147–155. doi:10.1159/00048876429847835
   PubMed Web of Science ®Google Scholar
• PaikS, ShakS, TangG, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–2826. doi:10.1056/NEJMoa04158815591335
   PubMed Web of Science ®Google Scholar
• WoodwardWA, BarlowWE, JagsiR, et al. Association between 21-gene assay recurrence score and locoregional recurrence rates in patients with node-positive breast cancer. JAMA Oncol. 2020;6(4):505–511. doi:10.1001/jamaoncol.2019.555931917424
   PubMed Web of Science ®Google Scholar
• TurashviliG, ChouJF, BrogiE, et al. 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2017;166(1):69–76. doi:10.1007/s10549-017-4381-728702894
   PubMed Web of Science ®Google Scholar
• MinnA, GuptaG, SiegelP, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436(7050):518–524. doi:10.1038/nature0379916049480
   PubMed Web of Science ®Google Scholar
• KimM-Y, OskarssonT, AcharyyaS, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315–1326. doi:10.1016/j.cell.2009.11.02520064377
   PubMed Web of Science ®Google Scholar
• ComenE, NortonL, MassagueJ. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol. 2011;8(6):369–377. doi:10.1038/nrclinonc.2011.6421522121
   PubMed Web of Science ®Google Scholar
• ChengCJ, LinYC, TsaiMT, et al. SCUBE2 suppresses breast tumor cell proliferation and confers a favorable prognosis in invasive breast cancer. Cancer Res. 2009;69(8):3634–3641. doi:10.1158/0008-5472.CAN-08-361519369267
   PubMed Web of Science ®Google Scholar
• LinY-C, Chen-C-C, ChengC-J, YangR-B. Domain and functional analysis of a novel breast tumor suppressor protein, SCUBE2. J Biol Chem. 2011;286(30):27039–27047. doi:10.1074/jbc.M111.24441821652720
   PubMed Web of Science ®Google Scholar
• LinYC, LeeYC, LiLH, ChengCJ, YangRB. Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition. J Cell Sci. 2013;127(1):85–100.24213532
   PubMed Web of Science ®Google Scholar
• MinKW, KimDH, DoSI, et al. Diagnostic and prognostic relevance of MMP-11 expression in the stromal fibroblast-like cells adjacent to invasive ductal carcinoma of the breast. Ann Surg Oncol. 2013;20(Suppl 3):S433–S442. doi:10.1245/s10434-012-2734-323115007
   PubMed Web of Science ®Google Scholar
• ZhangX, HuangS, GuoJ, et al. Insights into the distinct roles of MMP-11 in tumor biology and future therapeutics (Review). Int J Oncol. 2016;48(5):1783–1793. doi:10.3892/ijo.2016.340026892540
   PubMed Web of Science ®Google Scholar